Diag-Nose Medical Pty Ltd

Diag-Nose.io is a Melbourne-based biotechnology company specializing in precision diagnostics and therapies for chronic respiratory diseases including asthma, COPD, and chronic sinusitis. The company's flagship RhinoMAP platform combines nasal microsampling, proteomics, and AI-driven machine learning algorithms to decode airway biology and provide actionable clinical insights for ENT physicians. By analyzing patients' immune profiles and airway biology, Diag-Nose.io delivers personalized treatment recommendations that move beyond trial-and-error respiratory care. The ABEL Microsampler® device enables non-invasive nasal liquid biopsies for research and clinical diagnostics, with recent FDA and ARTG regulatory approvals. The platform targets treatment personalization and disease prevention through root-cause analysis, supporting precision medicine approaches for improved patient outcomes in respiratory disease management.